Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial

RCT (n=6007) of this oral antianginal agent that improves energy metabolism found that use over several years dose (35mg BD) in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or long term outcome vs placebo.

The Lancet